ArticleLiver international : official journal of the International Association for the Study of the Liver2026
An Automated Microfluidic System for Haemostasis Assessment in Cirrhosis With Thrombocytopenia.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Automated Microfluidic System for Haemostasis Assessment in Cirrhosis With Thrombocytopenia.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
BACKGROUND &
aimsConventional laboratory tests do not capture platelet-vessel wall interactions (primary haemostasis) occurring in vivo, limiting guidance before invasive procedures. This is relevant in patients with thrombocytopenia, hallmark of advanced cirrhosis. Microfluidic assays may overcome these limitations. The Total Thrombus Analysis System (T-TAS) is a flow chamber that can be adapted for thrombocytopenic samples when equipped with the HD-CHIP. The CirTAS study aimed to assess T-TAS reproducibility and the ability to identify a disease-severity gradient in patients with cirrhosis and thrombocytopenia.
methodsEighty-one patients with cirrhosis and thrombocytopenia were enrolled (20 Child-Pugh A, 41 B/C and 20 B/C with bacterial infection). T-TAS measurements were performed using the HD-CHIP. Reproducibility was assessed by intraclass correlation coefficients. Thromboelastometry (ROTEM) parameters were analysed in parallel. Multivariable and piecewise regression analyses were performed to test factors influencing T-TAS parameters.
resultsT-TAS showed high reproducibility, with intraclass correlation coefficients ≈0.90 for all parameters (p < 0.001), even in platelet counts < 50 × 10
conclusionsT-TAS is reproducible in thrombocytopenic cirrhosis and is associated with reduced thrombus formation alongside disease progression and bacterial infection. Platelet count and FVIII are the main determinants of thrombus formation assessed by T-TAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.